Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial
testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with
recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)